[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$f65-g5LTUgHIk8dGZIHhGe2pKpxnfW0g-O4HGxk3yxcs":3,"$f6tviOEoL5CyqHmXTJOs56v3oOHeRKQkceFtps_qWneQ":8,"$f4nraT15g7V7H6l_A_KymMy4D-Hy-sOVe93d_V8nipO4":54,"$fDbWCmkdw-mFs8y5qxPcjnAr6tNcDOF8V_WsJc3pYME8":58},{"code":4,"msg":5,"message":6,"data":6,"success":7},401,"认证失败，无法访问系统资源",null,false,{"code":9,"msg":10,"message":6,"data":11,"success":53},200,"操作成功",{"id":12,"specialistId":13,"specialistAssistants":14,"profilePhoto":15,"specialistName":16,"hospital":17,"department":18,"postsTitle":19,"materialTotal":20,"videoTotal":21,"isConcern":7,"title":22,"coverVertical":23,"coverAcross":24,"content":25,"description":26,"views":27,"likes":21,"isThumbsUp":7,"isCollection":7,"collections":21,"createTime":28,"seoTitle":22,"seoKeywords":29,"seoDescription":30,"shelvesTime":31,"version":20,"menus":32,"menuId":34,"type":41,"quality":52,"commentCount":21,"isComment":41},58769,870430,[],"https://cdn.haohuanjiao.com/learnMaterial/ystApp//cS9JVwmzuvXY2cQvRpyUXCisJse6z4Pa.png","陈茜","浙江大学医学院附属第一医院","呼吸内科","副主任医师",2,0,"肺癌G12C突变与纳武利尤单抗药品用药指南","","https://ystcdn.venuertc.com/venue/AI/b774785e-1efd-4f5b-ace9-3859244bba0f.jpg","\u003Cdiv class=\"drug-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">肺癌G12C突变与纳武利尤单抗药品用药指南\u003C/h1>\n  \u003Cdiv class=\"material-intro\">\n    \u003Cp>谈及免疫治疗，纳武利尤单抗（Nivolumab）是一种备受关注的PD-1抑制剂，已在多种治疗方案中被采用。其实，这类药物用法十分讲究，尤其是在配合针对G12C突变的个性化治疗时。下面我们就分7大环节，逐步拆解纳武利尤单抗的用药细节和注意事项，每一点都关乎安全和疗效。\u003C/p>\n  \u003C/div>\n\n  \u003Csection class=\"material-section material-bg-1\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">01 纳武利尤单抗的药物成分与剂型\u003C/h2>\n    \u003Cul>\n      \u003Cli>通用名：纳武利尤单抗（Nivolumab）\u003C/li>\n      \u003Cli>成分类型：人源化免疫球蛋白G4（IgG4）单克隆抗体\u003C/li>\n      \u003Cli>剂型规格：常见为100mg/10mL或40mg/4mL注射用浓溶液，每瓶单剂量，须稀释后使用\u003C/li>\n      \u003Cli>给药途径：静脉滴注，不用于皮下注射或口服\u003C/li>\n      \u003Cli>外观描述：无色至淡黄色澄明液体\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-note\">\n      \u003Cspan>📦\u003C/span>\n      \u003Cstrong>正确做法：\u003C/strong> 药物开封即用，最大限度减少污染风险。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-2\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">02 药理作用机制简析\u003C/h2>\n    \u003Cp>\n      纳武利尤单抗通过阻断PD-1（Programmed Death-1）受体，解除免疫抑制，从而提升机体免疫细胞活性。\u003Cbr>\n      其本质是“放开免疫系统的刹车”，使自身免疫系统可以更有效地识别并清除“异常细胞”。\n    \u003C/p>\n    \u003Cdiv class=\"material-tip\">\n      \u003Cspan>🧬\u003C/span>\n      \u003Cstrong>需要注意：\u003C/strong> 药理作用决定其特殊的副反应模式，必须紧密监测用药过程变化。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-3\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">03 纳武利尤单抗的标准用法与剂量\u003C/h2>\n    \u003Cp>\n      正确的用药方法对于获得最佳效果至关重要，但实际操作中细节非常多——\n    \u003C/p>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>剂量调整：\u003C/strong> 常用推荐为每2周或4周一次，最终剂量需按照体重、治疗方案及联合药物综合评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>稀释方式：\u003C/strong> 必须用0.9%氯化钠或5%葡萄糖溶液进行配制，45分钟内静脉输注。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>输注要求：\u003C/strong> 输注过程中需采用专用细菌过滤器，禁止与其他药品混合。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>常见联合用药：\u003C/strong> 在临床上上述静脉输注药物往往会与化疗药（如含铂方案）、防吐药、升白药物等按序联合使用。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-case\">\n      \u003Cspan>👩‍🔬\u003C/span>\n      \u003Cstrong>临床经验：\u003C/strong>一位53岁女性患者在联合化疗＋纳武利尤单抗治疗时，必须严格分开化疗药和免疫药物的配制及输注管路，有效避免药物不良反应和药物不相容问题。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-4\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">04 适应症与禁忌症分界\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>适应症：\u003C/strong> 纳武利尤单抗主要用于参与特定治疗方案。是否使用要结合基因检测和医生综合评估结果。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>禁忌症：\u003C/strong>\n        \u003Cul>\n          \u003Cli>对本品任何成分有严重过敏反应史者严格禁用。\u003C/li>\n          \u003Cli>需要同时使用严重免疫抑制药（如大剂量糖皮质激素）时慎重评估。\u003C/li>\n          \u003Cli>器官移植史、活动性自身免疫反应或严重感染等特殊情况需医生权衡。\u003C/li>\n        \u003C/ul>\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-warning\">\n      \u003Cspan>⚠️\u003C/span>\n      \u003Cstrong>特别提醒：\u003C/strong> 任何成分过敏史都必须提前告知医师，禁忌症下禁止自行使用。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-1\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">05 药物相互作用管理\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>免疫抑制剂：\u003C/strong> 同时服用环孢素、他克莫司等药物会显著影响纳武利尤单抗效应，需严格避免。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>糖皮质激素：\u003C/strong> 大剂量联合可抑制免疫活性，影响疗效，仅在必要时短期使用。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>联合化疗药物：\u003C/strong>\n        纳武利尤单抗通常可与多种化疗药物联合，但需确保各药物配制、输注严格分离。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>生物制剂与疫苗：\u003C/strong> 与活疫苗间隔时间应根据指南执行，减少不良反应风险。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\n      \u003Cspan>🔄\u003C/span>\n      \u003Cstrong>正确做法：\u003C/strong>\n      用药期间，应主动告知医生所有正在服用的药物与保健品清单。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-2\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">06 常见不良反应及处理建议\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>免疫相关副反应：\u003C/strong> 包括皮肤、肠道、肺、肝及内分泌系统异常。表现在皮疹、腹泻或肝酶增高等方面，发生率总体在15~25%之间\u003Csup>[1]\u003C/sup>。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>注射时不良反应：\u003C/strong> 可出现发热、寒战、过敏性反应，约3%患者有轻度不适。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>长期用药风险：\u003C/strong> 可能导致慢性免疫激活，跟进检测血常规、肝功能、电解质、甲状腺功能等指标。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-case\">\n      \u003Cspan>🩺\u003C/span>\n      \u003Cstrong>实际操作示例：\u003C/strong>\n      临床管理中，辅助药物如5-HT3拮抗剂可佐以减轻恶心或呕吐，升白药物有助缓解白细胞抑制风险。\n    \u003C/div>\n    \u003Cdiv class=\"material-tip\">\n      \u003Cspan>🚨\u003C/span>\n      \u003Cstrong>处理方法：\u003C/strong>\n      一旦有发热、严重皮肤反应或呼吸困难等异常，需立即暂停药物并就医处理。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-3\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">07 用药期间的特殊管理与日常操作\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>服药前准备：\u003C/strong> 建议按时复查血液、肝肾、免疫相关指标，必要时调整用药方案。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>输注过程风险控制：\u003C/strong> 全程留观，遇过敏、发热或其他异常需及时告知医护。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>辅助支持：\u003C/strong> 多数治疗方案会搭配止吐、升白及护胃等药物；这些药物按照医生处方分开使用，不可自行随意添换。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>避免自行停药：\u003C/strong> 紧急情况外，所有变更请由医师评估决定，即便出现轻度不适也需按医嘱处理，而非擅自停药。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>常规监测：\u003C/strong> 治疗期间须定期进行血常规、肝肾功能等化验促安全。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>漏药/过量：\u003C/strong> 忘记按时输注时，不要自行补量，应联系专业人士重新安排。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\n      \u003Cspan>🔬\u003C/span>\n      \u003Cstrong>正确做法：\u003C/strong>\n      记下每次用药时间，严格按照计划执行，不随意变更输注频次。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-4\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">08 药品储存要求与安全操作\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>储存温度：\u003C/strong> 纳武利尤单抗应在2~8℃冷藏避光保存，切勿冷冻。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>启封使用：\u003C/strong> 打开即用，稀释配制后须4小时内使用完毕。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>过期弃置：\u003C/strong> 超过有效期或外观异常切勿使用；剩余药液安全处理，严禁自行丢弃。\u003C/li>\n      \u003Cli>\n        \u003Cstrong>携带外出：\u003C/strong> 如需带药，必用便携冰袋冷藏，且不暴露在高温环境下。\u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-warning\">\n      \u003Cspan>❄️\u003C/span>\n      \u003Cstrong>必须执行：\u003C/strong>\n      用剩药品不得留存家庭环境，避免误用带来意外风险。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-1\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">09 特殊人群用药注意点\u003C/h2>\n    \u003Cul>\n      \u003Cli>\n        \u003Cstrong>老年患者：\u003C/strong> 按照肝肾功能、身体状况调整用量，安全性需评估。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>儿童：\u003C/strong> 纳武利尤单抗尚未普遍用于儿童，若特殊情况需专家会诊。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>孕妇及哺乳期：\u003C/strong> 妊娠、哺乳期尽量避免使用，仅在权衡利弊后由专科医生决定。\n      \u003C/li>\n      \u003Cli>\n        \u003Cstrong>肝肾功能受损：\u003C/strong> 中、重度组织损伤患者，必须个性化方案调整输注计划，确保体内药物代谢安全。\n      \u003C/li>\n    \u003C/ul>\n    \u003Cdiv class=\"material-tip\">\n      \u003Cspan>👶\u003C/span>\n      \u003Cstrong>操作建议：\u003C/strong>\n      特殊人群切勿照搬常规剂量方案，用前务必让医生充分知情所有健康信息。\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-2\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">10 总结&重点提示\u003C/h2>\n    \u003Cp>\n      纳武利尤单抗是一款机制独特的免疫调节药物，其静脉输注及冷藏管理、严格的适应症把控和详细的相互作用屏蔽都是保证疗效与安全的关键。\u003Cbr>\n      使用本品时，最关键的几条包括：始终依医嘱用药，切实做好不良反应监测，严禁自行停调剂量，以及妥善冷藏储存。发现异常勿犹豫，及时沟通医师。如此，才能发挥药物最大益处。\n    \u003C/p>\n    \u003Cdiv class=\"material-highlight\">\n      \u003Cspan>✨\u003C/span>\n      \u003Cstrong>要记住的最重要两点：\u003C/strong>\n      \u003Col>\n        \u003Cli>每次用药都确保环境和步骤规范，绝不混合输注其他药品。\u003C/li>\n        \u003Cli>倘若出现不适症状，尤其是发热、皮疹、持续疲乏，立即就医处理。\u003C/li>\n      \u003C/ol>\n    \u003C/div>\n  \u003C/section>\n\n  \u003Csection class=\"material-section material-bg-3\">\n    \u003Ch2 style=\"color: rgb(44, 62, 80); margin: 1.2em 0px 0.6em; font-weight: 700; border-bottom: 1px solid rgb(238, 238, 238);\">主要英文参考文献\u003C/h2>\n    \u003Col>\n      \u003Cli>\n        Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., ... & Pardoll, D. M. (2012). Safety, activity, and immune correlates of anti–PD-1 antibody in cancer. \u003Ci>New England Journal of Medicine\u003C/i>, 366(26), 2443-2454. https://doi.org/10.1056/NEJMoa1200690\n      \u003C/li>\n      \u003Cli>\n        Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., ... & Larkin, J. (2015). Nivolumab versus chemotherapy in patients with advanced melanoma: a 3-year overall survival analysis. \u003Ci>Journal of Clinical Oncology\u003C/i>, 33(17), 1935-1944. https://doi.org/10.1200/JCO.2014.59.5706\n      \u003C/li>\n      \u003Cli>\n        Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., ... & Larkin, J. (2015). Pembrolizumab versus ipilimumab in advanced melanoma. \u003Ci>New England Journal of Medicine\u003C/i>, 372(26), 2521-2532. https://doi.org/10.1056/NEJMoa1503093\n      \u003C/li>\n      \u003Cli>\n        Brahmer, J. R., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., ... & Reck, M. (2015). Health-related quality-of-life results for nivolumab versus docetaxel in advanced non-small-cell lung cancer: results from CheckMate 017 and CheckMate 057. \u003Ci>Lancet Oncol\u003C/i>, 17(7), 839-847. https://doi.org/10.1016/S1470-2045(16)30040-6\n      \u003C/li>\n    \u003C/ol>\n  \u003C/section>\n\u003C/div>\n\n\u003Cstyle>\n.drug-material-container {\n  margin: 40px auto;\n  max-width: 800px;\n  background: #f9fcff;\n  border-radius: 18px;\n  box-shadow: 0 2px 10px rgba(60,120,170,0.05);\n  padding: 24px 32px 32px 32px;\n  font-family: 'Segoe UI', 'PingFang SC', 'Arial', sans-serif;\n  color: #24364e;\n  font-size: 18px;\n  line-height: 1.7;\n}\n\n.material-title {\n  font-size: 2.3em;\n  font-weight: 700;\n  text-align: left;\n  margin-bottom: 26px;\n  padding-left: 6px;\n  color: #25498e;\n  border-left: 7px solid #87bdd8;\n}\n\n.material-intro {\n  background: linear-gradient(90deg, #e3f3fa 0%, #e8f5ee 100%);\n  padding: 16px 20px;\n  border-radius: 10px;\n  margin-bottom: 26px;\n  font-size: 1.02em;\n  color: #1f4566;\n  border-left: 7px solid #b8dee6;\n}\n\n.material-section {\n  margin-bottom: 30px;\n  padding: 24px 20px 18px 20px;\n  border-radius: 16px;\n  position: relative;\n  box-sizing: border-box;\n}\n\n.material-bg-1 {\n  background: linear-gradient(100deg, #e8f1ff 0%, #f3f8fa 100%);\n}\n\n.material-bg-2 {\n  background: linear-gradient(100deg, #f8f4fe 0%, #f7fdfd 100%);\n}\n\n.material-bg-3 {\n  background: linear-gradient(100deg, #f3faf5 0%, #f7f8fc 100%);\n}\n\n.material-bg-4 {\n  background: linear-gradient(100deg, #fcf9f5 0%, #f7f7ff 100%);\n}\n\n.material-section h2 {\n  font-size: 1.36em;\n  font-weight: 700;\n  margin-bottom: 13px;\n  color: #295792;\n  padding-left: 7px;\n  border-left: 4px solid #9fc6e8;\n}\n\n.material-section ul, .material-section ol {\n  margin: 10px 0 14px 32px;\n  padding: 0;\n}\n\n.material-section li {\n  margin-bottom: 9px;\n  padding-left: 1px;\n}\n\n.material-tip,\n.material-warning,\n.material-note,\n.material-case,\n.material-highlight {\n  margin: 12px 0 0 0;\n  padding: 10px 17px 10px 30px;\n  border-radius: 8px;\n  font-size: 1.01em;\n  position: relative;\n  min-height: 28px;\n}\n\n.material-tip {\n  background: #f0f8ff;\n  border-left: 5px solid #5cbce6;\n  color: #215e80;\n}\n\n.material-warning {\n  background: #fdebee;\n  border-left: 5px solid #ec7290;\n  color: #7d223a;\n}\n\n.material-note {\n  background: #fffbe0;\n  border-left: 5px solid #dbc44c;\n  color: #816a13;\n}\n\n.material-case {\n  background: #f7f6fe;\n  border-left: 5px solid #997ae1;\n  color: #4a346d;\n}\n\n.material-highlight {\n  background: #e0f9ed;\n  border-left: 5px solid #61c3ab;\n  color: #246451;\n  margin-top: 20px;\n}\n\n.material-tip span,\n.material-warning span,\n.material-note span,\n.material-case span,\n.material-highlight span {\n  font-size: 1.18em;\n  position: absolute;\n  left: 10px;\n  top: 10px;\n}\n\n.material-section sup {\n  color: #6e82c5;\n  font-size: 0.95em;\n}\n\n.material-section ol {\n  padding-left: 1.2em;\n  margin-left: 2em;\n}\n\n@media (max-width: 900px) {\n  .drug-material-container {\n    max-width: 97%;\n    padding: 10px 7px 15px 7px;\n  }\n  .material-section {\n    padding: 16px 7px 10px 7px;\n  }\n}\n\u003C/style>\n","\u003Cdiv class=\"drug-material-container\">\n  \u003Ch1 id=\"material_title\" class=\"material-title\" style=\"color:",514,"2025-08-13 16:08:47","纳武利尤单抗, 肺癌, G12C突变, 用药指南, 免疫治疗, 药物相互作用, 不良反应, 适应症","了解纳武利尤单抗在肺癌G12C突变个性化治疗中的应用指南，包括用法、剂量、注意事项，确保治疗安全有效。","2025-08-17 00:24:00",[33],{"menuId":34,"menuName":35,"parentId":21,"orderNum":20,"path":36,"component":37,"isFrame":38,"isCache":39,"menuType":40,"visible":41,"status":21,"createDept":6,"remark":23,"createTime":42,"children":43,"columnImage":44,"columnLogo":45,"uncheckedLogo":6,"checkedLogo":6,"isHot":41,"isHome":21,"forceLogin":21,"color":46,"seoTitle":47,"seoKeywords":48,"seoDescription":49,"contentNum":6,"promotionalPoster":50,"menuFrame":7,"innerLink":7,"parentView":7,"routeName":51,"routerPath":36,"componentInfo":37},"1986713082609147906","健康科普","article","/article.html","1","0","T",1,"2025-11-07 16:31:25",[],"https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:49/d4291d16-ed1c-48dd-84c8-ec1f85980b75.png","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:52/6fe64094-9416-442c-a66d-032fb292666a.png","#c8e6ca","健康科普助力健康中国2030:共享健康知识新理念","健康科普, 健康中国, 科普知识, 健康家庭, 性健康, 营养健康, 运动健康, 科普宣传","探索健康科普在健康中国行动中的重要角色,了解最新的健康科普创新大赛、动漫及短视频,传播健康知识,助力全民健康。","https://ystcdn.venuertc.com/venue/undefined/2026-01-24-18:08:56/bd33f471-6c54-4d1b-a364-b06973dbc144.png","Article","癌症肿瘤",true,{"code":9,"msg":10,"message":6,"data":55,"success":53},{"pageNo":41,"pageSize":56,"result":57,"totalSize":21},10,[],{"code":9,"msg":10,"message":6,"data":59,"success":53},{"authors":60,"appraiseDimensionScoresVos":61},[],[]]